Page last updated: 2024-12-06

pafenolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Pafenolol is a non-selective beta-blocker with a chemical structure similar to propranolol. It was originally developed for the treatment of hypertension and angina but is no longer widely used due to its relatively short half-life and potential side effects. It is a racemic mixture of two enantiomers, with the (S)-enantiomer possessing greater beta-blocking activity than the (R)-enantiomer. The compound has been studied for its potential in treating other conditions, including glaucoma and hyperthyroidism, but further research is needed to determine its efficacy and safety in these applications.'

pafenolol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71144
CHEMBL ID152371
SCHEMBL ID1055902
MeSH IDM0111403

Synonyms (35)

Synonym
pafenolol
PDSP2_000345
PDSP1_000347
CHEMBL152371 ,
1-{2-[4-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]-ethyl}-3-isopropyl-urea
bdbm50121973
1-[2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethyl]-3-propan-2-ylurea
75949-61-0
unii-5aep5yj9mz
pafenololum [inn-latin]
5aep5yj9mz ,
pafenololum
(+-)-1-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenethyl)-3-isopropylurea
pafenolol [inn]
SCHEMBL1055902
(+/-)-1-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenethyl)-3-isopropylurea
urea, n-(2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-n'-(1-methylethyl)-
pafenolol [who-dd]
83242-76-6
urea, n-(2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-n'-(1-methylethyl)-, (+/-)-
Q15634003
unii-qw8t7nk8x6
unii-e6x8cbk4rr
urea, n-(2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-n'-(1-methylethyl)-, (+)-
pafenolol, (-)-
QW8T7NK8X6 ,
178968-84-8
178968-79-1
(+)-n-(2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-n'-(1-methylethyl)urea
(-)-n-(2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-n'-(1-methylethyl)urea
pafenolol, (+)-
urea, n-(2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-n'-(1-methylethyl)-, (-)-
E6X8CBK4RR ,
1-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenethyl)-3-isopropylurea
DTXSID20868386

Research Excerpts

Overview

Pafenolol is a beta 1-adrenoreceptor antagonist exhibiting some interesting oral absorption properties in both rat and humans.

ExcerptReferenceRelevance
"Pafenolol is a beta 1-adrenoreceptor antagonist exhibiting some interesting oral absorption properties in both rat and humans. "( Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans.
Hoffmann, KJ; Lennernäs, H; Regårdh, CG; Renberg, L,
)
1.84
"Pafenolol is a beta-blocker with unusual oral absorption properties. "( Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile.
Lennernäs, H; Regårdh, CG, 1993
)
1.98

Bioavailability

ExcerptReferenceRelevance
" The mean bioavailability (F) of the oral dose was 27."( Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.
Gabrielsson, M; Heggelund, A; Kylberg-Hanssen, K; Lundborg, P; Regårdh, CG, 1990
)
0.52
" The blood concentration-time profile exhibits two peaks, and the bioavailability is low and dose-dependent due to an incomplete and nonlinear intestinal uptake."( Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans.
Hoffmann, KJ; Lennernäs, H; Regårdh, CG; Renberg, L,
)
0.39
" This indicates that the low bioavailability is due primarily to poor intestinal uptake."( Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.
Lennernäs, H; Regårdh, CG, 1993
)
0.5
" The blood concentration-time profile exhibits two peaks, and the bioavailability is low and dose dependent because of incomplete and nonlinear intestinal uptake."( Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile.
Lennernäs, H; Regårdh, CG, 1993
)
0.54
" The reported great similarity in apparent first-order absorption rate constants (k) of seven structurally diverse compounds between the two species were obtained."( Similarity in the linear and non-linear oral absorption of drugs between human and rat.
Chiou, WL; Chung, SM; Jeong, HY; Ma, C; Wu, TC, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
"5 h after dosing and a second higher maximum concentration was noted 3 to 5 h after the administration in the majority of the experiments."( Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.
Heggelund, A; Kylberg-Hanssen, K; Lundborg, P; Regardh, CG, 1990
)
0.6
" The major part of the absorption was associated with the second peak which appeared about 4 h after dosing in both starved and unstarved rats."( Pharmacokinetics of pafenolol in the rat: a suitable model for studying absorption mechanisms of a drug exhibiting unusual absorption properties in man.
Lenneräs, H; Regårdh, CG, 1990
)
0.6
" The 24-hour blood pressure and heart rate recordings showed a clear dose-response relationship for pafenolol that could not be detected by ordinary casual readings."( Monitoring 24-hour blood pressure in a drug trial. Evaluation of a noninvasive device.
Andersson, G; Berglund, G; Castenfors, J; De Faire, U; Hartford, M; Liedholm, H; Ljungman, S; Thulin, T; Wikstrand, J,
)
0.35
" After the terbutaline dose-response curve was determined, terbutaline was inhaled three times in increasing doses."( Pafenolol, a highly selective beta 1-adrenoceptor-antagonist, in asthmatic patients: interaction with terbutaline.
Löfdahl, CG; Marlin, GE; Svedmyr, N, 1983
)
1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Ki5.50000.02002.35948.5900AID150735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Ki15.50000.11002.02675.5000AID680132
ATP-dependent translocase ABCB1Homo sapiens (human)Ki23,200.00003.40003.40003.4000AID680132
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID680132TP_TRANSPORTER: inhibition of Verapamil binding in membranes from Vinblastine-induced Caco-2 cells1999Journal of pharmaceutical sciences, Oct, Volume: 88, Issue:10
Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
AID29139Calculated dissociation constant (pKa, calculated with ACD/pKa)2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID150735High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID150736Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (31.58)18.7374
1990's9 (47.37)18.2507
2000's2 (10.53)29.6817
2010's2 (10.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (21.74%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (78.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]